Lv2
200 积分 2025-08-24 加入
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
1个月前
已完结
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
2个月前
已完结
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
5个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
6个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
6个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
6个月前
已完结
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
6个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
6个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)]
6个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
6个月前
已完结
皖公网安备34019202002308
